EASL‑EASD‑EASO Guidance: resmetirom and semaglutide Recommended Use in MASH

This summary compiles the 2026 joint guidance, describing when to consider resmetirom or semaglutide, how to choose between them, and key monitoring points in non-cirrhotic MASH with moderate fibrosis (F2‑3).[1]

Study type: Journal Article, Practice Guideline（category: clinical guideline/high-quality systematic review） Published: Journal of hepatology，2026-12-01 Source: PubMed public abstract

This summary compiles the 2026 joint guidance, describing when to consider resmetirom or semaglutide, how to choose between them, and key monitoring points in non-cirrhotic MASH with moderate fibrosis (F2‑3).[1]

Why this guidance is worth attention

Why care about this guidance

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and the inflammatory phenotype MASH, besides long-term liver-related risks (such as cirrhosis, hepatocellular carcinoma, need for liver transplantation, etc.), also increase cardiovascular and metabolic complication risks. Non-invasive tests (NITs), such as vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE) or the ELF score, can be used instead of biopsy to identify high‑risk groups. When classified as high risk (NIT thresholds reported in the abstract, e.g. VCTE 10–20 kPa, MRE 3.1–5.0 kPa, ELF 9.8–11.3), the guidance suggests considering pharmacologic therapy, and provides recommendations and monitoring principles for resmetirom and semaglutide.[1]

What the guidance actually found

Key recommendations and points from the guidance (based on the guidance abstract)[1]

• Indication: It is recommended to consider adding pharmacologic therapy in non-cirrhotic MASH with fibrosis stage 2–3 (assessed by NIT or biopsy), alongside structured lifestyle intervention and optimization of comorbidities.
• Available drugs and doses (as listed in the guidance): resmetirom (oral 80 mg or 100 mg) and semaglutide (subcutaneous once weekly 2.4 mg).
• Individualized drug selection: Choice should be based on patient preferences, potential risks, and cardiorenal‑metabolic status (presence of obesity, type 2 diabetes [T2D], cardiovascular disease, or chronic kidney disease). The abstract notes that semaglutide may be favored in patients with obesity or T2D, or with established cardiovascular disease/high cardiovascular risk; resmetirom may be prioritized in non‑obese patients or in those already on or intolerant to GLP‑1RA.
• Monitoring and safety: The guidance recommends assessing nutritional status and sarcopenia risk when using semaglutide; and using fibrosis-related NITs to track treatment response and to determine stopping criteria.
• Patients with cirrhosis: For patients with MASH and established cirrhosis, the abstract states resmetirom and semaglutide currently appear safe but should not be used as targeted therapy for MASH until more evidence demonstrates benefit on liver-related outcomes.

Potential implications for patients with CKD, dialysis, or transplantation

How to interpret these recommendations (explained in three categories)

• Associations shown by the studies (as reported in the guidance): The guidance, based on existing evidence and expert consensus, considers that NITs can identify high‑risk patients and proposes a strategy to consider using resmetirom or semaglutide in non‑cirrhotic MASH patients with F2‑3 fibrosis; it also notes that semaglutide may confer cardiometabolic benefits in patients with obesity or T2D and those at high cardiovascular risk. These are associative statements noted in the guidance abstract.[1]

• Conclusions supported by sufficient evidence: As a clinical guideline, the guidance recommends that in appropriate non‑cirrhotic MASH patients, pharmacologic therapy should be combined with structured lifestyle modification and comorbidity management. This represents the practical conclusions summarized by the guidance rather than findings from a single trial.[1]

• Hypotheses not yet confirmed or remaining questions: Whether these two drugs can reduce major adverse liver outcomes (MALO; e.g., progression to cirrhosis, hepatocellular carcinoma, need for transplantation) in the long term remains to be confirmed by long‑term follow‑up studies; whether they provide liver benefits in patients with established cirrhosis is also not yet established and remains a question requiring more data.[1]

Current limitations of the evidence

Study and guidance limitations (limitations of the abstract source and this summary)

• This summary is based on the Journal of Hepatology guidance abstract on PubMed; the full text was not read for this summary.
• The abstract does not provide original study sample sizes or full methodological details; the guidance itself is a practice guideline and its recommendations may derive from multiple sources of evidence and expert consensus, but the abstract does not detail the quality or data of each original study.
• NIT thresholds may vary across populations and devices; clinical judgment should be applied individually. The thresholds listed in the abstract are reference ranges noted in the guidance.
• A single guideline abstract cannot represent all clinical scenarios or regional practices; individual patient treatment decisions still require professional clinical assessment.

Conclusions that remain uncertain

Questions not yet answered or requiring further research

• Whether long‑term use reduces MALO (major adverse liver outcomes) sufficiently is still under investigation.
• In MASH patients with established cirrhosis, it is not yet established that these two drugs improve liver outcomes; thus they are not currently recommended as definitive targeted therapy for MASH in cirrhosis.
• More data are needed on safety and efficacy specifics in patients with chronic kidney disease, across different age groups, and in diverse populations.
• Practical details such as when to start, when to stop therapy, and which NIT changes should be used as thresholds for efficacy remain to be refined.

(The above uncertainties are as stated in the guidance abstract)[1]

Questions to discuss with your medical team

• Do I fall into the group for whom the guidance recommends considering pharmacologic therapy (for example, what are my NIT results or fibrosis stage)?
• In my case, which drug—resmetirom or semaglutide—is more appropriate? What are the advantages and disadvantages of each?
• What common or important adverse effects might occur with these drugs? How will nutritional status and sarcopenia risk be monitored?
• Which tests will be used to monitor treatment response during therapy (which NITs, and at what frequency)? How often will they be done?
• If I also have diabetes, cardiovascular disease, or chronic kidney disease, how would these drugs affect my overall treatment plan?
• If I am already on another GLP‑1RA or have a history of drug intolerance, what does the guidance recommend?
• If I already have cirrhosis, are these two drugs appropriate for me? (The abstract indicates they should not be considered targeted MASH therapy in cirrhosis.)

How to read this study (our interpretation)

This section was written by the Beyond CKD editor — a kidney-transplant recipient with a health-management background, not a physician — using only the PubMed abstract. We have not read the full paper, and no clinician has reviewed this text. It is meant to help you understand the numbers, not to advise treatment.

What the study asked

This is not a study but joint clinical guidance from the European liver (EASL), diabetes (EASD) and obesity (EASO) societies on two newly approved drugs for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) — resmetirom and semaglutide — covering who should receive them, how to start, monitor and stop.

How to read the results

The logic is: identify high-risk people with non-invasive tests first, then consider drugs. Specific cut-offs are given — transient elastography (VCTE, “FibroScan”) 10–20 kPa, MR elastography 3.1–5.0 kPa, ELF blood score 9.8–11.3 — ranges that mark high fibrosis risk and can replace liver biopsy. Drug therapy is recommended for adults with non-cirrhotic MASH and fibrosis stage 2–3, always alongside structured lifestyle intervention and management of other conditions. For choice of drug: semaglutide (2.4 mg weekly by injection) is preferred when obesity, type 2 diabetes, cardiovascular disease or high cardiovascular risk is present, because of its added cardiometabolic benefits; resmetirom (80 or 100 mg orally) is prioritised for people without obesity or who already take or cannot tolerate a GLP-1 agonist. Semaglutide requires monitoring for nutrition and muscle loss. In people who already have MASH cirrhosis, both drugs appear safe but are not recommended as MASH-targeted treatment yet.

Limitations

Guidance reflects expert judgement of existing trials, not new data, and the abstract does not grade the evidence behind each recommendation. Whether either drug reduces hard long-term outcomes (cirrhosis, liver cancer, transplantation) is still being tested. The document is written for European health systems; approval, reimbursement and price vary widely elsewhere.

What it means for readers and people with kidney disease

Fatty liver disease is common in people with CKD, diabetes and after transplantation. The value of this guidance is in saying that not every fatty liver needs a drug — staging with non-invasive tests comes first — and that lifestyle change remains a condition of treatment. It lists kidney disease among the cardio-renal-metabolic factors to weigh when choosing a drug, but gives no CKD-specific dosing or contraindication detail.

How to check further

Ask your doctor: Have I had a FibroScan or ELF test, and what is my fibrosis stage? Given my kidney function and medications (especially anti-rejection drugs), do either of these drugs interact or carry a contraindication for me?

Original abstract: PubMed 42805503 (https://pubmed.ncbi.nlm.nih.gov/42805503/). Interpretation last updated 2026-11-06.

References

[1] （作者資訊見原文）. EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.. Journal of hepatology. 2026. DOI: 10.1016/j.jhep.2026.08.028. PMID: 42805503.

Medical disclaimer: This article is for general health education and information only. It does not constitute individual medical diagnosis, treatment advice, or a doctor–patient relationship. Medical research is continually updated, and study findings have their own scope and limitations. Every patient's condition, laboratory values, medications and treatment needs differ. Do not stop or adjust medication doses, change your diet or fluid intake, or alter dialysis or transplant treatment based on this article alone. For any medical questions, please consult your nephrologist or another qualified healthcare professional.

Article created: 2026-10-27｜Original research published: 2026-12-01｜Last checked: 2026-10-27 (source metadata cross-checked with PubMed)